Bienvenue sur le nouveau Boursorama. Découvrez tout ce qui a changé
  1. Aide
    1. Espace client
    2. Connexion
Accès membre Boursorama

Erreur d'authentification

Vous êtes authentifié. Nous chargeons votre espace membre.

Mot de passe oublié ?

Nouveau sur Boursorama ? Devenez membre

Identifiant/Mot de passe oublié
Si vous êtes Membre de la Communauté Boursorama, veuillez indiquer l'adresse email que vous avez fournie lors de votre enregistrement pour recevoir votre identifiant et/ou ré-initialiser votre mot de passe :

Nouveau sur Boursorama ? Devenez membre

Fermer

Actualités

NATUREX

134.20EUR
+0.30% 
Ouverture théorique 134.20

FR0000054694 NRX

Euronext Paris données temps réel
Politique d'exécution
  • ouverture

    134.00

  • clôture veille

    133.80

  • + haut

    134.20

  • + bas

    134.00

  • volume

    10 244

  • valorisation

    1 281 MEUR

  • capital échangé

    0.11%

  • dernier échange

    24.04.18 / 17:35:28

  • limite à la baisse

    Qu'est-ce qu'une limite à la hausse/baisse ?

    Fermer

    120.80

  • limite à la hausse

    Qu'est-ce qu'une limite à la hausse/baisse ?

    Fermer

    147.60

  • Éligibilité

    SRD

    Qu'est-ce que le SRD ?

    Fermer
    PEA

    Qu'est-ce que le PEA ?

    Fermer
    PEA-PME

    Qu'est-ce que le PEA-PME ?

    Fermer

Autres places de cotation

Fermer
  • + Alerte

  • + Portefeuille

    Ajouter NATUREX à un portefeuille virtuel

    Fermer
  • + Liste

    Ajouter NATUREX à mes listes

    Fermer

NATUREX : Launch of a Eur 15 million capital increase with preferential subscription rights maintained

Boursorama05/02/2009 à 12:00

Avignon - February 5, 2009 - At its meeting of February 3, 2009, the Board of Directors of Naturex Group approved a capital increase of € 15 million with the preferential rights of the company's existing shareholders maintained.

This equity issue will consolidate Naturex's financial structure after a period of strong organic growth buoyed by a dynamic expansion policy: acquisition, in 2007, of Hammer Pharma and HP Botanicals in Italy and Chart Corporation in the US, and of Berkem's "Actifs innovants" division in 2008.

Funds raised will allow to maintain strong organic growth. Between one quarter and one third of the funds raised may be set aside to finance future acquisitions.

The company SGD, controlled by Jacques Dikansky, which, along with Naturex's directors, hold 17.64% of its capital as at January 31, 2009, has declared its intention to subscribe to new shares in the amount of € 11,306,920. SGD's maximum subscription is expected to represent 75% of the planned issue.

Key terms of the operation

Initial number of new shares to be issued

The initial number of new shares to be issued is set at 753,794, and may be increased to 759,749 if all of the share warrants awarded by Naturex and which may be taken up before February 17, 2009 are exercised.

Issue price

The issue price is set at € 20 per share. It is calculated based on the average share price recorded during the 20 trading days preceding February 3, 2009, namely € 25.19 minus a discount of 20.6%. The issue price represents a discount of 12.6% on the theoretical ex-rights price calculated on February 3, 2009.

Percentage of the capital and voting rights represented by the new shares

Naturex's share capital amounted to € 4,522,765.50 on January 31, 2009 and consists of 3,015,177 shares with a par value of € 1.50. Accordingly, the capital increase of € 15,075,888 through the issue of 753,794 new shares will, upon completion, represent 20% of the company's capital and 18.95% of its voting rights such as they stood on that same date.

If all of the warrants awarded by Naturex and which may be taken up before February 17, 2009 are exercised, the capital increase will represent 20.13% of the company's capital and 19.07% of its voting rights.

Extension clause

Depending on the scale of demand, Naturex may decide to increase the number of new shares to be issued by a maximum of 113,069, i.e. 15% of the initial offer.

Dividend due date

Shares will be eligible for dividends on January 1, 2008.

Preferential subscription rights

Each shareholder will be granted a preferential subscription right per share held at the close of trading on February 5, 2009.

Subscription procedure

Preferential rights will entitle holders to subscribe to shares on a non-reducible basis at a rate of 1 new share for 4 old shares, disregarding fractional shares.

Subscriptions may also be made on a reducible basis.

Theoretical unit value of Naturex preferential subscription rights and shares ex-rights

Based on its closing price on February 3, 2009, namely € 23.62, and on the issue price of € 20, the theoretical unit value of Naturex preferential subscription rights stands at € 0.72, and the theoretical unit value of its shares ex-rights at € 22.90.

Listing of preferential subscription rights

Preferential subscription rights will be detached from shares on February 5, 2009 after the close of the markets. They will be traded on NYSE Euronext - Euronext Paris from February 6, 2009 to February 20, 2009 inclusive, under ISIN code FR0010720565.

Listing of new shares

New shares will be issued on March 5, 2009 and traded under the same ISIN code as existing Naturex shares, namely FR0000054694.

Subscription intention of the main shareholders

The company SGD which, along with Naturex's directors, holds 17.63% of its capital as at January 31, 2009, has declared its written, firm and irrevocable intention to exercise all of its preferential subscription rights (16.57% of capital) on a non-reducible basis, and to subscribe to new shares in the amount of € 11,306,920 on a reducible basis.

SGD's maximum subscription is expected to represent 75% of the planned issue.

The Banque de Vizille, which holds 6.04% of the capital prior to this issue, has declared its intention to exercise half of its preferential subscription rights.

Naturex is not aware of the intentions of any other shareholders to exercise or sell their preferential subscription rights.

Lead Manager

CIC Vizille Capital Finance

Gross and net proceeds of the share issue

Based on the issue price of € 20 per new share, the gross proceeds from the issue (extension clause excluded) should amount to € 15.08 million, issue premium included. Extension clause excluded again, gross proceeds could increase to € 15.19 million if all of the warrants awarded by Naturex and which may be taken up before February 17, 2009 are exercised.

Based on the issue price of € 20 per new share, the net proceeds from the issue (extension clause excluded) should amount to € 14.88 million, issue premium included. Extension clause excluded again, net proceeds could increase to € 14.99 million if all of the warrants awarded by Naturex and which may be taken up before February 17, 2009 are exercised.

Indicative timetable

February 4, 2009

Approval of the prospectus by the French market authority, the AMF

February 5, 2009

Publication of a press release announcing the launch of the operation
Publication of the Notice of Share Issue on NYSE Euronext
Detachment of preferential subscription rights (after close of trading)

February 6, 2009

Opening of subscription period and listing of preferential subscription rights

February 20, 2009  

Closing of subscription period and listing of preferential subscription rights

March 2, 2009

Decision regarding the application of the extension clause

March 3, 2009

Publication of the Offer of New Shares on NYSE Euronext
Publication of a press release indicating the final amount of the capital increase and the proportion of reducible subscriptions

March 5, 2009

Settlement Delivery / Listing / Certificate of depository

Risk factors

Investors should consider the risks outlined in Chapter II.2 of the Registration Document, Chapter 4 of the Update of the Registration Document and Chapter 2 of the Transaction Notice.

Documents and prospectus

All corporate documentation is available to the public at Naturex's head office: Site d'Agroparc, Espace Pinède, BP 1218, 84911 Avignon Cedex 9.

The prospectus approved by the AMF includes:

o   the registration document filed with the AMF on April 30, 2008 under D.08-0344,
the update of the registration document of February 3, 2009 filed under D.08-0344-A01,
o   the transaction notice containing the summary of the prospectus.

Copies of the prospectus approved by the AMF on February 4, 2009 under No. 09-027 are available, free of charge, from Naturex's head office. It is also available on the company's website (www.naturex.com) and on the website of the AMF (www.amf-france.org).

If you would like to receive financial information about Naturex by e-mail, register at:
www.actus-finance.com


Naturex has been listed on Euronext Paris, segment C since October 1996
ISIN FR0000054694 - Reuters NATU.LN - Bloomberg NRX:FP

About Naturex
Naturex develops, manufactures and markets natural ingredients for the food, dietary supplement and nutraceutical, pharmaceutical, and cosmetic industries. Headquartered in Avignon, France, the group employs 570 people and has an international reach, with over 90% of its sales generated in 30 different countries outside France, 60% of which in North America. Naturex has production facilities in France, Morocco, the United States and Italy, subsidiaries in China and the United Kingdom, and representative offices in Germany and Singapore. www.naturex.com

Naturex contacts: Actus Finance contacts:
Jacques Dikansky, Chairman and CEO
Tel : +33 (0)4 90 23 96 89
naturex@naturex.com

Thierry Lambert, Deputy Chief Executive Officer 
Tel : +33 (0)4 90 23 96 89
t.lambert@naturex.com
Laurence Marquézy, Investor Relations
Tel : + 33 (0)1 72 74 82 23
lmarquezy@actus.fr

Anne Catherine Bonjour, Press Relations
Tel : + 33 (0)1 53 67 36 93
acbonjour@actus.fr

This press release constitutes neither an offer to sell nor a solicitation to subscribe to Naturex shares in the United States of America or in any other country where such an offer would be contrary to the applicable laws and regulations. Naturex shares have not been and will not be registered in the sense of the U.S. Securities Act of 1933, as amended (the "US Securities Act"), and cannot be offered or sold in the United States of America.

This press release does not contain or constitute an invitation or an incitement to invest. It is intended solely for persons who (1) are not in the United Kingdom, (2) have professional investment experience, (3) come under the scope of application of Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended).

The dissemination, publication or distribution of this press release in certain countries may constitute a violation of the existing laws and regulations. As a result, persons physically present in these countries and in which this press release is disseminated, distributed or published must inquire as to any local restrictions and comply with them. No copy of the press release can be distributed or sent to the United States of America, Canada or Japan.

Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-15025-2009-02-05_naturex_ak_vf_uk.pdf
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free

                    

Valeurs associées

+0.30%

Mes listes

valeur

dernier

var.

Les Risques en Bourse

Fermer

Note d'information importante

Chère Cliente, Cher Client,

Nous souhaitons vous donner quelques règles à suivre pour investir dans les meilleures conditions et vous présenter les risques potentiels auxquels vous êtes susceptibles d'être exposés.

Vos connaissances, Votre profil d'investisseur
Tout d'abord évaluez vos connaissances boursières et financières et formez-vous en consultant le Guide de l'Investisseur, véritable introduction à la bourse et à l'épargne qui est disponible sur votre site Boursorama Banque sous la rubrique «Aide/Formation».
Définissez ensuite votre profil d'investisseur (prudent, équilibré, dynamique) et vos objectifs (durée de placement, rentabilité …). Ce constat vous permettra de vous orienter vers les produits et les marchés qui vous sont le mieux adaptés.

Pensez à vos besoins de liquidité
Adaptez votre durée de placement (1 mois, 1 an, 5 ans, …) à vos besoins de liquidités (projets, impôts …) et en tout état de cause, n'investissez pas en Bourse une partie trop importante de votre patrimoine.

La composition de votre portefeuille
Etudiez la composition de votre portefeuille : diversifiez vos placements afin de réduire au maximum le risque inhérent à un support ou à un secteur en particulier et n'investissez pas dans les produits optionnels (warrants, certificats), fortement risqués, si votre portefeuille n'est pas suffisamment important.

Connaître la vie des Sociétés
Renseignez-vous sur la société au sein de laquelle vous envisagez d'investir (actualités, santé financière, opérations à venir, …).

Agir en connaissance de cause
Soyez conscient des risques auxquels vous êtes exposés : de fait, si certains produits (actions volatiles, warrants, certificats, future…) ou certains modes d'investissement (Service de Règlement Différé) augmentent les espérances de gain, ils accroissent aussi fortement le risque de perte (totale). Ainsi, une connaissance technique préalable approfondie est requise, c'est pourquoi nous conseillons aux néophytes de s'écarter de ce type de produits.

Des risques différents selon les marchés
Prenez connaissance des caractéristiques des marchés sur lesquels vous allez investir : vous êtes confrontés à un risque variable (liquidité, volatilité, niveau d'information, change…) selon les marchés sur lesquels vous décidez d'intervenir (Premier Marché, Second Marché, Nouveau marché, Marché Libre, Marché étranger…).

Figez vos pertes
Enfin, la règle d'or à retenir est de savoir figer ses pertes : à vous de définir le montant de perte acceptable dès le début et une fois ce niveau atteint agissez en conséquence.

En appliquant ces quelques règles de bonnes conduite vous serez à même de mieux appréhender votre risque lorsque vous allez investir sur les Marchés

Un ensemble de cours complets sur la Bourse est également mis à votre disposition gratuitement et que vous pouvez retrouver sur votre site Boursorama Banque dans la rubrique «Aide/Formation». Si des questions resteraient en suspend, n'hésitez pas à contacter votre agence qui est à votre disposition.

Cordialement,
L'équipe de Boursorama Banque.